scholarly journals Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues

2016 ◽  
Vol 9 (2) ◽  
pp. 520-525 ◽  
Author(s):  
Ana Ortolá Buigues ◽  
Irene Crespo Hernández ◽  
Manuela Jorquera Moya ◽  
Jose Ángel Díaz Pérez
Keyword(s):  
Somatostatin Receptors ◽  
Somatostatin Analogues ◽  
Somatostatin Analogue ◽  
Continuous Administration ◽  
Antiangiogenic Effect ◽  
Neurological Improvement ◽  
Radiological Response ◽  
Multiple Meningioma ◽  
Multiple Recurrences

Medical treatment of meningiomas is reserved for cases in which surgery and radiotherapy have failed. Given that a high percentage of meningiomas express somatostatin receptors, treatment with somatostatin analogues has been proposed. In addition, these medications have been shown to have an antiproliferative and antiangiogenic effect in vitro. To date, very few cases with clinical response and none with radiological response have been described. The case described here is the first to report a radiological response. A 76-year-old Caucasian male was first diagnosed with unresectable meningioma at age 47. The patient experienced multiple recurrences and underwent three surgeries and radiotherapy over the years from the initial diagnosis. Despite treatment, the disease continued its progression. Based on an Octreoscan positive for tumour uptake, therapy with extended-release somatostatin analogues was started. Although no clinical neurological improvement was observed, magnetic resonance imaging scans revealed a discreet but continuous radiological response over time. After >2 years of continuous administration of lanreotide, the patient remains progression free. In highly selected cases, somatostatin analogue treatment for meningioma may be beneficial. Based on our findings, treatment with somatostatin analogues should be maintained longer than previously described before evaluating treatment response.

[111In-DTPA-D-Phe1]Octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

1994 ◽  
Vol 131 (6) ◽  
pp. 577-581 ◽  
Author(s):  
Eva Tiensuu Janson ◽  
Jan-Erik Westlin ◽  
Barbro Eriksson ◽  
Håkan Ahlström ◽  
Sten Nilsson ◽  
...  
Keyword(s):  
Predictive Value ◽  
Somatostatin Receptor ◽  
Somatostatin Receptors ◽  
Somatostatin Analogues ◽  
University Hospital ◽  
Somatostatin Analogue ◽  
Carcinoid Tumours ◽  
Malignant Carcinoid ◽  
Receptor Scintigraphy ◽  
Octreotide Scintigraphy

Tiensuu Janson E, Westlin J-E, Eriksson B, Ahlström H, Nilsson S, Öberg K. [111In-DTPA-D-Phe1]Octrotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994:131:577–81. ISSN 0804–4643 This study was performed to evaluate whether the presence or absence of somatostatin receptors in malignant carcinoid tumours detected by [111In-DTPA-D-Phe1]octreotide scintigraphy can be used to predict response to somatostatin analogue treatment. Thirty patients were investigated, 28 with midgut carcinoid tumours and two with foregut carcinoid tumours. Twenty-seven patients showed pathological uptake in tumour lesions at scintigraphy: of these, 22 responded to somatostatin analogue treatment using octreotide, somatuline or octastatin, while five patients failed to respond. None of the three patients displaying negative scintigraphic investigations responded to treatment with somatostatin analogues. These results show a good correlation between the somatostatin receptor status and the patients' ability to respond to somatostatin analogue treatment (p = 0.014). We conclude that somatostatin receptor scintigraphy using [111In-DTPA-D-Phe1]octreotide can be used to select patients with malignant carcinoid tumours suitable for somatostatin analogue treatment and exclude those that will not benefit from such medication. Eva Tiensuu Janson, Dept of Internal Medicine, University Hospital, S-751 85 Uppsala, Sweden

90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4594-4594
Author(s):  
C. Toumpanakis ◽  
A. Quigley ◽  
R. Srirajaskanthan ◽  
L. Marelli ◽  
T. Singhrao ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptors ◽  
Somatostatin Analogues ◽  
Response To Treatment ◽  
Bone Marrow Toxicity ◽  
Who Grade ◽  
Early Results ◽  
Disease Stabilization ◽  
Radiological Response ◽  
Grade Ii

4594 Background: The expression of somatostatin receptors (SSTR) on Neuroendocrine Tumors (NETs) has led not only to tumour visualization utilizing SSTR scintigraphy, but also to the development of receptor-targeted radionuclide therapy. Isotopes such as 111-Indium, 90-Yttrium and 177-Lutetium are linked to somatostatin analogues and then internalized by tumour cells. The recent development of the peptide Octreotate has higher affinity for type 2 SSTR than Octreotide. Aim: to estimate efficacy and tolerability of 90-Yttrium-tyr3-DOTA-octreotate in patients with metastatic progressive NETs. Methods: 89 patients (median age: 51.5 years) with metastatic NETs were studied. All patients had shown signs of progression despite previous treatments. In all patients, the tumours had shown good uptake either in the OctreoScan or in the Ga-68 octreotate PET scan. 64 patients received 3 cycles and 25 patients received 2 cycles of 90-Yttrium-tyr3-DOTA-octreotate. The mean i.v. dose/cycle was 3100 MBq. 29/89 patients included a cycle of intra-arterial therapy with mean dose/cycle 2090 MBq for large volume liver disease. Symptomatic response to treatment was defined as the reduction of >50% to the symptom score and radiological response utilized RECIST criteria. Results: In all patients the post treatment scintigraphy demonstrated good uptake and localization by the tumors. In 59/89 (66%) symptomatic response was achieved. Utilizing RECIST criteria, 50/89 (56%) had disease stabilization (SD) of previously progressive disease and 7 (8%) had partial response (PR). 31/89 (35%) had continued tumor progression. The SD/PR (n=57) group had sustained response for median 17.2 months. Bone marrow toxicity (WHO grade II) was noted in 15/89 (16.8%), persistent in 4 patients with significant bone metastases. Four patients developed mild renal failure (WHO grade II), that was irreversible in one of them. Conclusions: 90Y-DOTA-octreotate is a well-tolerated and safe treatment for patients with progressive neuroendocrine tumors. Early results regarding efficacy are promising. No significant financial relationships to disclose.

scholarly journals Antitumour Effects of Somatostatin Analogues in the Treatment of Neuroendocrine Tumours

2012 ◽  
Vol 08 (03) ◽  
pp. 156
Author(s):  
Diogo Assed Bastos ◽  
Brenda Gumz ◽  
Frederico Costa ◽  
◽  
◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Antitumour Activity ◽  
Somatostatin Receptors ◽  
Somatostatin Analogues ◽  
Antiangiogenic Activity ◽  
Tumour Shrinkage ◽  
Phosphotyrosine Phosphatases ◽  
Antitumour Effects

Neuroendocrine tumours (NETs) are rare and heterogeneous neoplasms that can present with functional syndromes due to the hypersecretion of peptides. Somatostatin analogues (SSAs) have been used since the 1980s for the treatment of neuroendocrine tumours, with the aim of controlling the symptoms of functioning tumours and improving patients’ quality of life. Data from preclinical studies offer evidence of both direct and indirect mechanisms by which SSAs can exert antitumour effects. The activation of somatostatin receptors by SSAs leads to the activation of phosphotyrosine phosphatases, which control downstream apoptotic and antiproliferation signalling pathways. Also, the suppression of secretion of several growth factors and inhibition of antiangiogenic activity by SSAs indirectly inhibits tumour cell proliferationin vitro. Previous uncontrolled studies had shown tumour shrinkage and disappearance in response to the SSA octreotide. Recent results from the randomised and placebo-controlled PROMID trial have demonstrated that octreotide has antitumour activity in patients with metastatic mid-gut NETs. This article examines recent data providing evidence of the antitumour activity of somatostatin analogues.

Antitumour Effects of Somatostatin Analogues in the Treatment of Neuroendocrine Tumours

2010 ◽  
Vol 8 (2) ◽  
pp. 94
Author(s):  
Diogo Assed Bastos ◽  
Brenda Gumz ◽  
Frederico Costa ◽  
◽  
◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Antitumour Activity ◽  
Somatostatin Receptors ◽  
Somatostatin Analogues ◽  
Antiangiogenic Activity ◽  
Tumour Shrinkage ◽  
Phosphotyrosine Phosphatases ◽  
Antitumour Effects

Neuroendocrine tumours (NETs) are rare and heterogeneous neoplasms that can present with functional syndromes due to the hypersecretion of peptides. Somatostatin analogues (SSAs) have been used since the 1980s for the treatment of neuroendocrine tumours, with the aim of controlling the symptoms of functioning tumours and improving patients’ quality of life. Data from preclinical studies offer evidence of both direct and indirect mechanisms by which SSAs can exert antitumour effects. The activation of somatostatin receptors by SSAs leads to the activation of phosphotyrosine phosphatases, which control downstream apoptotic and antiproliferation signalling pathways. Also, the suppression of secretion of several growth factors and inhibition of antiangiogenic activity by SSAs indirectly inhibits tumour cell proliferationin vitro. Previous uncontrolled studies had shown tumour shrinkage and disappearance in response to the SSA octreotide. Recent results from the randomised and placebo-controlled PROMID trial have demonstrated that octreotide has antitumour activity in patients with metastatic mid-gut NETs. This article examines recent data providing evidence of the antitumour activity of somatostatin analogues.

scholarly journals Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

2005 ◽  
Vol 12 (4) ◽  
pp. 683-699 ◽  
Author(s):  
G A Kaltsas ◽  
D Papadogias ◽  
P Makras ◽  
A B Grossman
Keyword(s):  
Neuroendocrine Tumours ◽  
Performance Status ◽  
Somatostatin Receptors ◽  
Tumour Response ◽  
Somatostatin Analogues ◽  
Symptomatic Improvement ◽  
Tumour Regression ◽  
Somatostatin Analogue ◽  
Tumour Mass ◽  
Pancreatic Islet Cell

Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell membrane-specific peptide receptors, such as somatostatin receptors (SSTRs), and of which gastroenteropancreatic (GEP), carcinoid and pancreatic islet cell tumours exhibit the highest expression of SSTRs. Radiolabelled receptor-binding somatostatin analogues (octreotide and lanreotide) act as vehicles to guide radioactivity to tissues expressing SSTRs, and can thus be used for their diagnosis and treatment. After the localization of NETs bearing SSTRs with 111In-octreotide (OctreoScan), a number of radioisotopes with different physical properties have been used for their treatment. The administration of high doses of the Auger electron and γ-emitter 111In-diethylenetriaminepenta-acetic acid (DTPA)0,octreotide in patients with metastatic tumours has been associated with considerable symptomatic improvement but relatively few and short-lived objective tumour responses. The use of another radiolabelled somatostatin analogue coupled with 90Y, a pure β-emitter, 90Y-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)0,Tyr3,octreotide (90Y-DOTATOC, OctreoTher), was associated with 10–30% objective tumour response rates, and appears to be particularly effective in larger tumours. 111In- and 90Y-DOTA-lanreotide has also been used for the treatment of NETs although its therapeutic efficacy is probably inferior to that of octreotide-based radiopharmaceuticals. More recently, treatment with 177Lu-DOTA0,Tyr3octreotate (177Lu-DOTATATE), which has a higher affinity for the SSTR subtype 2, resulted in approximately 30% complete or partial tumour responses; this radiopharmaceutical is particularly effective in smaller tumours. Furthermore, treatment using both 90Y-DOTATOC and 177Lu-DOTA0,Tyr3octreotate seems promising, as the combination of these radiopharmaceuticals could be effective in tumours bearing both small and large lesions. Tumour regression is positively correlated with a high level of uptake on 111In-octreotide scintigraphy, limited tumour mass and good performance status. In general, better responses have been obtained in GEP tumours than other NETs. The side effects of this form of therapy are relatively few and mild, particularly when kidney-protective agents are used. Treatment with radiolabelled somatostatin analogues presents a promising tool for the management of patients with inoperable or disseminated NETs, and particularly GEP tumours.

scholarly journals Simultaneous Visualization of 161Tb- and 177Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 536
Author(s):  
Francesca Borgna ◽  
Patrick Barritt ◽  
Pascal V. Grundler ◽  
Zeynep Talip ◽  
Susan Cohrs ◽  
...  
Keyword(s):  
Pharmacokinetic Profile ◽  
Somatostatin Analogues ◽  
Distribution Coefficients ◽  
Spect Imaging ◽  
Cell Uptake ◽  
Organ Distribution ◽  
Dual Isotope ◽  
Biodistribution Studies ◽  
Simultaneous Visualization

The decay of terbium-161 results in the emission of β¯-particles as well as conversion and Auger electrons, which makes terbium-161 interesting for therapeutic purposes. The aim of this study was to use dual-isotope SPECT imaging in order to demonstrate visually that terbium-161 and lutetium-177 are interchangeable without compromising the pharmacokinetic profile of the radiopharmaceutical. The 161Tb- and 177Lu-labeled somatostatin (SST) analogues DOTATOC (agonist) and DOTA-LM3 (antagonist) were tested in vitro to demonstrate equal properties regarding distribution coefficients and cell uptake into SST receptor-positive AR42J tumor cells. The radiopeptides were further investigated in AR42J tumor-bearing nude mice using the method of dual-isotope (terbium-161/lutetium-177) SPECT/CT imaging to enable the visualization of their distribution profiles in the same animal. Equal pharmacokinetic profiles were demonstrated for either of the two peptides, irrespective of whether it was labeled with terbium-161 or lutetium-177. Moreover, the visualization of the sub-organ distribution confirmed similar behavior of 161Tb- and 177Lu-labeled SST analogues. The data were verified in quantitative biodistribution studies using either type of peptide labeled with terbium-161 or lutetium-177. While the radionuclide did not have an impact on the organ distribution, this study confirmed previous data of a considerably higher tumor uptake of radiolabeled DOTA-LM3 as compared to the radiolabeled DOTATOC.

scholarly journals In Vitro Pharmaco-Toxicological Characterization of Melissa officinalis Total Extract Using Oral, Pharynx and Colorectal Carcinoma Cell Lines

Processes ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 850
Author(s):  
Kristine Guran ◽  
Roxana Buzatu ◽  
Iulia Pinzaru ◽  
Madalina Boruga ◽  
Iasmina Marcovici ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Melissa Officinalis ◽  
Pharmacological Profile ◽  
In Ovo ◽  
Total Extract ◽  
Antiangiogenic Effect ◽  
Beneficial Effects ◽  
Gram Positive Bacteria ◽  
Potential Benefits

Melissa officinalis is a medicinal herb with an extensive pharmacological profile that has been proven to have beneficial effects in oral and gastrointestinal disorders. However, the effects of this plant in oral, pharyngeal, and colorectal malignancies, types of cancer with an increased incidence in recent years, are less investigated. The present study aims to evaluate the pharmacological profile of a Melissa officinalis total extract for potential benefits in oral, pharynx and colorectal carcinoma. The LC-MS profile of MO total extract (MOte) indicated a rich content in polyphenols, data that support the potent antioxidant capacity exhibited and the antimicrobial activity against both Gram-negative and Gram-positive bacteria. In addition, MOte triggered a dose-dependent and selective decrease in the viability of tumor cells (tongue and pharynx squamous cell carcinomas, and colorectal adenocarcinoma), with the most significant effect being recorded at 100 µg/mL. At the same concentration, MOte exhibited an antiangiogenic effect by inhibiting the process of angiogenesis in ovo. Overall, our findings support the potential benefits of Melissa officinalis leaf total extract as a valuable candidate for the prophylaxis of oral, pharyngeal and colorectal neoplasms.

Effective Therapy of Insulinoma by Using Long-Acting Somatostatin Analogue. A Case Report and Literature Review

2011 ◽  
Vol 120 (02) ◽  
pp. 68-72 ◽  
Author(s):  
A. Jawiarczyk ◽  
M. Bolanowski ◽  
J. Syrycka ◽  
G. Bednarek-Tupikowska ◽  
M. Kałużny ◽  
...  
Keyword(s):  
Adrenal Gland ◽  
Somatostatin Receptors ◽  
Subcutaneous Administration ◽  
Pancreatic Neuroendocrine Tumor ◽  
Somatostatin Analogue ◽  
Left Adrenal Gland ◽  
Glucose Levels ◽  
Long Acting ◽  
The Right

AbstractWe are reporting a case of 68-year-old woman with insulinoma, after a non-successful tumor surgery and a long-term diazoxide treatment. She had a lot of hypoglycemia cases, and a weight gain of 50 kg. An abdominal CT scan demonstrated a tumor 28 mm in the diameter, in the head of the pancreas. The patient did not agree for the repeated insulinoma surgery. Furthermore, we found a lesion in the left adrenal gland (14 mm in the diameter) and in the right lung (8 mm in the diameter). Pheochromocytoma was diagnosed on the basis of hypertension, elevated levels of normetanephrine in the 24-h urine collection, and an elevated level of norepinephrine in a plasma sample. After the left adrenal gland removal we observed lower blood pressure. Since we had revealed the presence of somatostatin receptors by the somatostatin receptors scintigraphy, we decided to control hypoglycemia by a monthly subcutaneous administration of the long-acting lanreotide. Because of higher glucose levels (300–400 mg/dl) we started an intense insulin therapy. Nowadays, the patient feels better, she has lost 20 kg of her body weight, and we have observed normal blood glucose levels during the long-term lanreotide treatment. We have noticed neither side effects nor hypoglycemic episodes and we have reduced the dose of insulin. The presented case can be an evidence of the effective treatment of the pancreatic neuroendocrine tumor of insulinoma type, with somatostatin analogue.

scholarly journals Cortistatin Is Not a Somatostatin Analogue but Stimulates Prolactin Release and Inhibits GH and ACTH in a Gender-Dependent Fashion: Potential Role of Ghrelin

Endocrinology ◽  
2011 ◽  
Vol 152 (12) ◽  
pp. 4800-4812 ◽  
Author(s):  
José Córdoba-Chacón ◽  
Manuel D. Gahete ◽  
Ana I. Pozo-Salas ◽  
Antonio J. Martínez-Fuentes ◽  
Luis de Lecea ◽  
...  
Keyword(s):  
Metabolic Phenotype ◽  
Somatostatin Analogue ◽  
Growth Hormone Secretagogue Receptor ◽  
Growth Hormone Secretagogue ◽  
Ancestral Gene ◽  
Ghrelin Receptor ◽  
Physiological Relevance

Cortistatin (CST) and somatostatin (SST) evolve from a common ancestral gene and share remarkable structural, pharmacological, and functional homologies. Although CST has been considered as a natural SST-analogue acting through their shared receptors (SST receptors 1–5), emerging evidence indicates that these peptides might in fact exert unique roles via selective receptors [e.g. CST, not SST, binds ghrelin receptor growth hormone secretagogue receptor type 1a (GHS-R1a)]. To determine whether the role of endogenous CST is different from SST, we characterized the endocrine-metabolic phenotype of male/female CST null mice (cort−/−) at hypothalamic-pituitary-systemic (pancreas-stomach-adrenal-liver) levels. Also, CST effects on hormone expression/secretion were evaluated in primary pituitary cell cultures from male/female mice and female primates (baboons). Specifically, CST exerted an unexpected stimulatory role on prolactin (PRL) secretion, because both male/female cort−/− mice had reduced PRL levels, and CST treatment (in vivo and in vitro) increased PRL secretion, which could be blocked by a GHS-R1a antagonist in vitro and likely relates to the decreased success of female cort−/− in first-litter pup care at weaning. In contrast, CST inhibited GH and adrenocorticotropin-hormone axes in a gender-dependent fashion. In addition, a rise in acylated ghrelin levels was observed in female cort−/− mice, which were associated with an increase in stomach ghrelin/ghrelin O-acyl transferase expression. Finally, CST deficit uncovered a gender-dependent role of this peptide in the regulation of glucose-insulin homeostasis, because male, but not female, cort−/− mice developed insulin resistance. The fact that these actions are not mimicked by SST and are strongly gender dependent offers new grounds to investigate the hitherto underestimated physiological relevance of CST in the regulation of physiological/metabolic processes.

Sign in / Sign up

Export Citation Format

Share Document